Scripps Research expands Board of Overseers with three esteemed members of the life science community

LA JOLLA, CA, and JUPTER, FL—Scripps Research has appointed three new members to its Board of Overseers, bringing additional strength to an influential body of leaders in biotechnology, pharmaceuticals, academia, law, science policy and investment.

The Board of Overseers, established in 2018 by Scripps Research’s President and CEO Pete Schultz, PhD, amplifies the institute’s advisory network and provides support for philanthropic efforts that ensure critical research is pursued to its fullest extent.

“We are privileged that so many highly respected and successful business leaders in the field of life science are helping us broaden our impact as a nonprofit scientific institute,” says Pete Schultz, PhD, president and CEO of Scripps Research. “More than ever, the world needs innovative science—and a framework that enables great science to be translated efficiently into life-saving medicines.”

The newest members of the Board of Overseers are Brian Dovey, a partner at life science venture capital firm Domain Associates, where he has served on the board of more than 35 companies and has been chairman of six; Stacy Kellner Rosenberg, retired attorney, noted philanthropist and former nonprofit leader who is an ardent supporter of science; and Sandford (Sandy) Smith, former executive vice president of Genzyme, CEO of two biopharma companies and a board member of multiple publicly traded biotech companies, where he focuses on commercial strategy.

“We welcome these three impressive individuals to our Board of Overseers and are excited for the important work that lies ahead,” Schultz says.